(NYSE: BHVN) Biohaven's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.
Biohaven's earnings in 2026 is -$586,841,000.On average, 19 Wall Street analysts forecast BHVN's earnings for 2026 to be -$451,877,680, with the lowest BHVN earnings forecast at -$510,679,024, and the highest BHVN earnings forecast at -$150,666,172. On average, 19 Wall Street analysts forecast BHVN's earnings for 2027 to be -$363,577,485, with the lowest BHVN earnings forecast at -$492,916,275, and the highest BHVN earnings forecast at -$248,995,673.
In 2028, BHVN is forecast to generate -$311,119,980 in earnings, with the lowest earnings forecast at -$486,995,359 and the highest earnings forecast at -$207,760,721.